Surveillance Of Genital Tract Complications Of Patients With Breast Cancer On Tamoxifen Therapy By Ultrasound In Iraqi Female

Abstract

Background: Tamoxifen, a triphenylethylene estrogen receptor modulator, which is treatment used in breast cancer patients, all patients receiving Tamoxifen should undergo regular Pelvic ultrasonography evaluations. This study conducted to determine the prevalence genital tract complications of tamoxifen treatments by ultrasonography examinations.

Method: This prospective study carried out at in the Oncology and Nuclear medicine specialist Hospital, Mosul/Iraq, from February 2018 to November 2018;there were 14 premenopausal and 36 postmenopausal patients. The inclusion criteria were as patients of breast cancer which had being on tamoxifen therapy.Fifty patients were included during a period of 10 months. The following parameters assessed by ultrasound, endometrial thickness, and echo texture of endometrium, uterus shape and ovaries conditions, with clinical parameter, age of patients, weight of patients,associated symptoms & mastectomy side.

Results: Fifty- patients receiving tamoxifen treatment enrolled in this study,increase endometrial thickness which measured by U/S in relation with increase duration of receiving tamoxifen which was significantly relation, with increase duration of receiving tamoxifen theirs increase incidence of ultrasound cystic changes of endometrial thickness,pelvic ultrasound  in which shows 10(20%)  of them complaining of ovarian cyst , which 3 (6%) of RT ovary and 7 (14%) of LT ovary, were shows relation with duration of tamoxifen.

Conclusion: Breast cancer patients during tamoxifen treatment should be under close ultrasonography surveillance examination every 4-6 months or at least annually.